xbiotech 产品代理
xbiotech 产品代理
XBiotech的技术为我们提供了独特的能力来开发病毒或细菌感染性疾病的候选药物。我们的核心发现技术使直接从人类血液样本中提取抗体疗法得以快速开发，这些抗体疗法可用于中和传染病。我们的真人抗体疗法允许我们概括从免疫献血者获得的自然免疫的关键组成部分。我们将这一发现计划与一个新颖的制造平台相结合，以促进快速的商业规模生产。我们相信，我们在发现和创造新的、有效的传染病治疗方法，包括迅速应对传染病爆发方面的能力在制药行业是无与伦比的。
Pipeline
INTERLEUKIN-1⍺
INFECTIOUS DISEASES
SARS-COV-2 / COVID-19
CLINICAL
Pioneering the technology behind groundbreaking antibody therapy treatments.
True Human™ monoclonal antibodies are derived from those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. XBiotech believes that naturally occurring monoclonal antibodies have the potential to be safer, more effective and faster to develop than their non-naturally occurring counterparts. The Company is developing a pipeline of product candidates targeting both inflammatory and infectious diseases and has developed commercial scale manufacturing technology and infrastructure that reduces the cost and time to launch new product candidates. The Company’s discovery and manufacturing technology makes XBiotech uniquely suited to rapidly identify neutralizing antibodies from humans and to quickly manufacture these product candidates for human use.
TECHNOLOGIES
XBiotech’s technologies provide us with the unique ability to develop drug candidates for viral or bacterial infectious diseases. Our core discovery technology enables the rapid development of antibody therapies directly from human blood samples that can be used to neutralize infectious disease. Our True Human antibody therapies allow us to recapitulate key components of the natural immunity obtained from an immune blood donor. We combine this discovery program with a novel manufacturing platform to facilitate rapid commercial-scale production. We believe our capabilities are unparalleled in the pharmaceutical industry to discover and create novel, effective treatments for infectious disease, including rapidly addressing infectious disease outbreaks.
FACILITIES
XBiotech has a fully integrated research and manufacturing center and a separate infectious disease research laboratory at its campus headquarters in Austin, Texas. The Company is now expanding its manufacturing center, with additional inventory area and personnel offices to accommodate greater output, a larger workforce, and around-the-clock manufacturing operations. A new 30,000 square foot infectious disease R&D center is also planned for construction on the campus adjacent to the existing R&D and manufacturing center.
